Hair-loss forums have turned "the half-life is five weeks, so weekly is plenty" into received wisdom. It is pharmacology, applied to the wrong dose. Go back to the pre-approval pharmacokinetic modelling, the dose-ranging trials and the little human data on spaced schedules, and the picture is clear enough to take a position on: once weekly at 0.5 mg is the weakest-supported way to take this drug, and the one randomised trial that tested it in humans found it did nothing measurable to the tissue it was meant to shrink.
This is not a finasteride-versus-dutasteride comparison; our finasteride vs dutasteride breakdown covers that. It is one question: if you have already chosen oral dutasteride, how often should the capsule go in?
Starting from
$1.60
Free consultation

3.8 AHF · 3.2 Trustpilot
Among the lowest sildenafil prices in telehealth — fits low-frequency users on tight budgets, with persistent customer-service watch points.
Get Started FreeThe five-week half-life belongs to a different dose
Start with what the US label actually says. The terminal elimination half-life of dutasteride is approximately five weeks at steady state, and the average steady-state serum concentration after a year on 0.5 mg a day is 40 ng/mL [1]. Daily dosing reaches about 65% of that steady state after one month and about 90% after three months. Because the drug clears so slowly from that level, it remains detectable in blood for four to six months after a man stops, which is why the label tells patients not to donate blood for six months after their last dose [1].
Every one of those statements is about a man who has been taking 0.5 mg every day for weeks. None of them is about a single capsule.
The reason they differ is that dutasteride has two elimination routes running in parallel. Gisleskog and colleagues gave 32 healthy men single doses ranging from 0.01 mg to 40 mg and modelled what happened [2]. At high concentrations, a slow linear pathway dominates, and that pathway produces the half-life of up to five weeks everyone quotes. But there is also a faster, saturable pathway. As serum concentration falls toward roughly 1 ng/mL, that faster route takes over a larger share of the clearance, and the half-life drops to about three days [2]. The authors' own simulations concluded that at a daily dose of 0.1 mg, the steady-state concentration and how quickly it is reached are mainly governed by the fast nonlinear pathway; only above 1 mg a day is the slow pathway almost entirely in charge [2].
GSK's own prescribing information in other markets spells out the threshold. Below about 3 ng/mL, dutasteride is cleared rapidly by both pathways, and single doses of 5 mg or less showed rapid clearance with a short half-life of three to nine days. Above 3 ng/mL, it is cleared slowly, with a terminal half-life of three to five weeks [3].
Now do the arithmetic for the weekly regimen. One 0.5 mg capsule a week averages out to about 0.07 mg a day. That is below the 0.1 mg daily dose at which the modellers said the fast pathway is already in charge [2]. A man taking one capsule every Sunday never builds up to the 40 ng/mL plateau that gives the drug its famous persistence. He spends the week in the concentration range where dutasteride's half-life is measured in days, not weeks.
That is the error at the centre of the weekly argument. "It lasts five weeks, so weekly keeps levels stable" assumes the slow pathway applies. At 0.5 mg once a week, it mostly does not; the daily regimen earns its long half-life by keeping concentrations high enough to saturate the fast route.
We will not put a number on how far serum levels fall between weekly doses. Nobody has published a simulation of a 0.5 mg weekly regimen, and inventing a curve is what a medical article should not do. The direction is not in doubt, and the direction is what matters.
What daily dosing actually buys you in DHT suppression
Dutasteride blocks both type 1 and type 2 5-alpha-reductase, the enzymes that convert testosterone to dihydrotestosterone (DHT). The question for any schedule is how much DHT it suppresses, and how steadily.
At the labelled dose, the answer is: almost all of it. The label reports median serum DHT reductions of 85% after one week of 0.5 mg daily and 90% after two weeks; in men treated for four years, the median reduction held at 93% to 95% [1]. In the dose-ranging trial in men with enlarged prostates, 0.5 mg daily cut DHT by a mean of 94.7%, and 5 mg by 98.4%, compared to 70.8% for finasteride 5 mg [4]. The 0.5 mg suppression was also far less variable from man to man than finasteride's.
Below 0.5 mg, suppression falls off with dose. In the first hair-loss dose-ranging trial, Olsen and colleagues randomised 416 men aged 21 to 45 to dutasteride 0.05, 0.1, 0.5 or 2.5 mg daily, finasteride 5 mg, or placebo for 24 weeks [5]. Scalp and serum DHT fell in a dose-dependent fashion, and so did the hair response; 2.5 mg beat finasteride on hair count at 12 and 24 weeks [5]. As the Thai group that later tested intermittent dosing summarises that trial, 0.1 mg daily cut serum DHT by about 70%, roughly what finasteride 5 mg managed [7].
The larger phase 3 trial, 917 men aged 20 to 50 across Asia and Latin America, ran dutasteride at 0.02, 0.1 and 0.5 mg daily against finasteride 1 mg and placebo [6]. Hair count and hair width rose with dose. At 0.5 mg, dutasteride beat finasteride 1 mg on hair count (P = .003), hair width (P = .004) and panel photographic assessment (P = .002), and adverse events were similar across groups [6]. According to the Thai group's summary of the two trials, 0.02 mg daily was no different from placebo, while 0.05 and 0.1 mg daily did produce significant hair gains [7].
Now set the weekly arithmetic against those points. One 0.5 mg capsule a week averages about 0.07 mg a day, between the 0.05 mg and 0.1 mg daily arms. On total dose alone, that might at best perform like low-dose daily dutasteride, with DHT suppression nearer finasteride's range than dutasteride's. And that assumes one weekly lump works as well as the same amount spread over seven days. The pharmacokinetics say it probably doesn't, and the Thai trial below adds evidence that it doesn't.
There is one data point that seems to cut the other way. In 2004, Leonard Marks at UCLA presented a study at the American Urological Association meeting, reported by Urology Times, in which men took dutasteride or finasteride for 28 days and then stopped for a week [10]. Dutasteride's DHT suppression barely moved in the week off: mean DHT was 37.5 pg/mL at day 28 and 38.3 pg/mL a week later. Finasteride's suppression largely collapsed over the same week [10]. The same report says a weekly 3.5 mg dose, the full weekly total in one go, produced DHT levels close to those of 0.5 mg daily [10].
Read carefully, it supports our argument. The men who held suppression through a week off had spent 28 days loading daily, which put them in the slow-clearance range. The weekly regimen that matched daily used seven capsules at once, not one. And Marks himself, per the report, cautioned against intermittent 0.5 mg dosing because its clinical effects had not been studied [10]. Treat it with the caution it deserves: this is a trade-press account of a conference presentation, sample size unreported, and we could not find a full peer-reviewed publication of the weekly arm.
The only once-weekly trial in humans was in prostates, and the weekly arm did nothing
There is, as far as we can find, no published trial of once-weekly oral dutasteride for hair loss. A search of the trial registries and the literature turns up nothing with a once-weekly hair-loss arm. That gap matters more than any number below, and it is worth stating before you read a forum post that implies otherwise.
The closest thing is a urology trial, and it is uncomfortable reading for the weekly camp. Abou-Farha and colleagues in Egypt randomised 300 men with enlarged prostates (over 40 cc) to tamsulosin plus dutasteride 0.5 mg on one of three schedules: daily, every other day, or once a week, and followed them for a year [9].
| Outcome at 12 months | Daily | Every other day | Once weekly |
|---|---|---|---|
| Prostate volume, cc (before → after) | 63.71 → 50.29 | 65.25 → 51.63 | 63.12 → 60.94 (P = 0.119, not significant) |
| Symptom score (IPSS) | Improved | Improved | Improved |
| Erectile function (IIEF-5) | Fell, 14.60 → 11.14 | No significant change | No significant change |
Prostate shrinkage is the clinical readout of tissue DHT suppression. It is the reason dutasteride is prescribed for an enlarged prostate. Daily and every-other-day dosing both shrank the gland by around 13 to 14 cc. Once-weekly dosing did not significantly shrink it at all [9]. Symptom scores improved in every group, but every group was also on daily tamsulosin, which relieves symptoms by a different mechanism, so that improvement says little about the dutasteride.
The sexual-function column is the trade-off, and it is real. Daily dutasteride plus tamsulosin pulled erectile-function scores down; the spaced schedules did not [9]. The authors' conclusion was that every-other-day dosing kept the prostate effect and spared sexual function. That conclusion is supported by their table. A conclusion that once-weekly works is not.
The study has limits. It does not describe blinding, it did not measure serum DHT, and the tissue is the prostate, not the scalp. But both respond to DHT through the same enzymes, and if once weekly cannot move the organ dutasteride is approved to treat, the burden of proof for hair sits with whoever recommends it.
The every-other-day result is the genuinely useful finding. It averages 0.25 mg a day, half the labelled dose, and matched daily on prostate volume, consistent with concentrations staying high enough for the slow pathway to carry the drug between doses. On these numbers, the line between "works" and "doesn't" falls somewhere between every second day and every seventh.
The hair data stops at twice a week
For hair specifically, the evidence on spaced dosing comes from two places, and neither goes as low as once a week.
The first is a retrospective series from a Madrid hair unit. Vañó-Galván and colleagues reviewed 307 men who had taken oral dutasteride for at least 12 months; they defined "low dose" as three or fewer 0.5 mg capsules a week [8]. Among the 42 men on dutasteride alone, 90% improved and none worsened. No adverse events were recorded in men on low doses, while eight men overall stopped for side effects such as reduced libido and gynaecomastia [8]. As the Thai authors describe the low-dose subgroup, twelve men took 0.5 mg twice or three times weekly; none progressed, eight had mild improvement, and none had marked improvement, whereas men on five or seven doses a week were more likely to show marked improvement [7]. It is a useful real-world signal. It is also retrospective, small in the relevant subgroup, and not randomised.
The second is the first randomised trial of spaced dutasteride for hair. Sereepanpanich and colleagues at Srinakharinwirot University in Bangkok randomised 60 Thai men aged 21 to 60 with Norwood IIIv to V hair loss to dutasteride 0.5 mg twice weekly, dutasteride 0.5 mg three times weekly, or finasteride 1 mg daily for 24 weeks [7]. Investigators and outcome assessors were blinded; the men were not. Pill-count adherence ran 97% to 99%.
The results:
| 24 weeks | Dutasteride 2×/week | Dutasteride 3×/week | Finasteride 1 mg daily |
|---|---|---|---|
| Terminal hair count change, hairs/cm² | +7.74 | +17.43 | +12.81 |
| Hair diameter change, μm | +2.58 | +5.88 | +4.66 |
| Moderate-to-marked photographic improvement | 21% | 35% | 21% |
| Any sexual adverse event | 10% | 5% | 15% |
Three findings matter for the weekly question. First, the dose-response held even at these low exposures: three times a week clearly beat twice a week on terminal hair count (P = .025) and diameter (P = .019) [7]. Fewer doses meant less effect. Second, neither dutasteride arm significantly beat daily finasteride on hair count (P = .23 and .27), and twice weekly came out numerically worse than finasteride [7]. Third, and the authors flag this themselves, the results don't line up with the daily dose-ranging data. Twice weekly averages about 0.14 mg a day, more than the 0.1 mg daily dose that matched or beat finasteride in earlier trials, yet it underperformed finasteride here. The authors' reading is that the same total dose given intermittently may not be equivalent to the same dose given continuously [7], which is what the pharmacokinetic model predicts.
Extend that down to once a week, which is half the twice-weekly exposure, and there is nothing in this trial to suggest you would beat daily finasteride. The trend runs firmly the other way.
Sixty men, one ethnic group, 24 weeks and unblinded participants make this a pilot, and the authors call it one. It was university-funded, with no conflicts declared [7]. But it is the best randomised evidence on spacing dutasteride for hair, and its message is consistent: the further you spread the doses, the less you get.
Why the side-effect case for weekly dosing is weaker than it looks
The real motivation for weekly dosing is usually not convenience. It is fear of sexual side effects, and that is a reasonable concern.
The evidence that sexual side effects are dose-dependent within dutasteride's usual range is weaker than most men assume. The Thai authors reviewed the dose-ranging trials and noted that decreased libido was reported at similar rates across daily doses from 0.01 to 0.5 mg, with a higher rate only at 2.5 mg [7]. In the 917-man phase 3 trial, adverse events were similar across all dutasteride doses, finasteride and placebo [6]. And in the Thai trial itself, sexual adverse events ran 10% on twice weekly, 5% on three times weekly and 15% on daily finasteride. Those differences were not statistically significant, and the trial was too small to detect differences of that size [7].
Pointing the other way are the Madrid series, with no adverse events in the low-dose group [8], and the Egyptian trial, where only the daily arm lost erectile function [9]. One is retrospective; the other was in men in their late 60s on an alpha-blocker. Together they make a plausible, unproven case that spacing doses spares some men.
So the honest trade looks like this. Going from daily to every second or third day probably costs you some hair effect and may buy you some tolerability. Going all the way to once a week, on the evidence available, costs you most of the effect, with no demonstrated tolerability gain over three times weekly. If the weekly regimen works mainly because it barely does anything, then it is not a gentler dutasteride. It is a weaker one.
There is also a structural point specific to this drug. Because dutasteride lingers for months once it has built up, a man who develops side effects on daily dosing cannot switch it off quickly [1]. That is a genuine argument for starting with a spaced schedule and moving up, rather than starting high and hoping. It is an argument for three times weekly as a cautious starting point, not for once weekly as a destination.
Where this leaves a man choosing a schedule
Pull it together and the ranking is not close.
Daily 0.5 mg is the only schedule with large randomised trials behind it for hair, the approved dose for hair loss in Japan, South Korea and Taiwan [7], and the regimen where the five-week half-life actually applies. If maximum DHT suppression is the goal, it is the better choice, full stop.
Every other day has the best evidence among the spaced options. It matched daily on prostate volume in a 300-man randomised trial, with better erectile-function scores [9]. It has not been tested for hair specifically, so that is an inference, but it is a well-founded one.
Three times weekly is the spaced schedule with randomised hair data. It was roughly comparable to daily finasteride on hair count and ahead on photographic improvement [7]. For a man who wants more than finasteride but is wary of daily dutasteride, it is the most defensible compromise.
Twice weekly underperformed daily finasteride in the only randomised hair trial [7]. Hard to recommend unless something specific rules out more frequent dosing.
Once weekly at 0.5 mg has no hair trial, failed on its tissue endpoint in the only human trial that tested it [9], and averages a dose at which the drug's fast clearance pathway dominates [2]. It is the weakest option on the evidence, and the one most often recommended online.
Any of these is off-label for hair loss in the US. Dutasteride's US approval is for benign prostatic hyperplasia at 0.5 mg once daily, and the label also notes that it lowers PSA by about 50% within three to six months. Any man on it, at any schedule, needs his doctor to establish a new PSA baseline and read later results with that in mind [1]. That makes the prescriber relationship matter more than it does for finasteride.
Practically, not every telehealth service will write dutasteride. Among the platforms we track, Sesame Care runs real clinician visits where an off-label schedule can be discussed, Maximus lists dutasteride in its hair-loss catalog, and Strut Health offers it alongside oral minoxidil and compounded formulas. Raise the schedule explicitly at the consult; do not assume a refill will default to anything other than daily.
If you look at this evidence and decide dutasteride is more than you want, the comparison worth making is against well-run finasteride, which the Thai trial put roughly level with three-times-weekly dutasteride on hair count. Hims and Roman both run straightforward finasteride and minoxidil subscriptions. MangoRx combines finasteride and minoxidil in a single daily chewable. DudeMeds and PeterMD suit men who already manage TRT or other care there and want hair treatment on the same account. Compare every hair-loss provider side by side, or start with our hair restoration overview if you are still deciding between drug classes. For men whose main worry is systemic exposure, our review of topical dutasteride vs topical finasteride covers the route that sidesteps the scheduling question altogether.
The trial that would settle this question is not complicated: daily, three times weekly and once weekly 0.5 mg, randomised and blinded, with serum DHT and hair counts at 6 and 12 months. Nobody has run it. Until someone does, any confident claim that "once a week is enough" goes beyond the evidence.
Frequently asked questions
Is once-weekly dutasteride enough to stop hair loss?
There is no published trial of once-weekly oral dutasteride for hair loss, so nobody can say it is. The closest evidence points the wrong way. In a randomised trial of 300 men with enlarged prostates, 0.5 mg once a week did not significantly shrink the prostate after a year, while daily and every-other-day dosing did [9]. The lowest frequency tested for hair, twice weekly, did worse than daily finasteride on hair count [7].
Doesn't the five-week half-life mean weekly dosing keeps levels steady?
Only at concentrations that daily dosing produces. The five-week figure applies at steady state on 0.5 mg a day [1]. At low concentrations, a faster elimination pathway takes over and the half-life drops to about three days [2], and GSK's own label puts the threshold at roughly 3 ng/mL, with single doses of 5 mg or less clearing in three to nine days [3]. One capsule a week keeps a man in that fast-clearance range.
What is the lowest dutasteride schedule with good evidence for hair?
Three times weekly. In a 60-man randomised trial it increased terminal hair count by 17.43 hairs/cm² over 24 weeks, compared to 12.81 on daily finasteride. The difference was not statistically significant, but three times weekly was clearly better than twice weekly [7]. Every other day has stronger evidence for DHT-driven tissue effects, but it was tested in the prostate rather than the scalp [9].
Will taking dutasteride less often reduce sexual side effects?
Possibly, but the evidence is thinner than it seems. Across daily dose-ranging trials, decreased libido was reported at similar rates from 0.01 to 0.5 mg [7]. In a prostate trial, only the daily arm saw erectile-function scores fall [9], and a retrospective series recorded no adverse events in men on three or fewer capsules a week [8]. Spacing doses may help some men, but there is no evidence that once weekly helps more than three times weekly.
Could a higher single weekly dose work instead?
A 2004 conference report described a 3.5 mg once-weekly dose producing DHT levels close to 0.5 mg daily [10]. That is seven capsules at once, it has never been tested for hair, and the investigator cautioned against intermittent regimens until they were studied. It is not a protocol to copy without a prescriber who understands the pharmacokinetics.
Sources
- [1] AVODART (dutasteride) capsules, US prescribing information, DailyMed
- [2] Gisleskog et al., The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination, British Journal of Clinical Pharmacology, 1999
- [3] Avodart professional information, GlaxoSmithKline South Africa (SAHPRA), 2015
- [4] Clark et al., Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, Journal of Clinical Endocrinology & Metabolism, 2004
- [5] Olsen et al., The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss, Journal of the American Academy of Dermatology, 2006
- [6] Gubelin Harcha et al., A randomized, active- and placebo-controlled study of different doses of dutasteride versus placebo and finasteride in male androgenetic alopecia, Journal of the American Academy of Dermatology, 2014
- [7] Sereepanpanich et al., Efficacy and safety of twice- or thrice-weekly dutasteride versus daily finasteride in men with androgenetic alopecia, JAAD International, 2025
- [8] Vañó-Galván et al., Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice, Dermatologic Therapy, 2020
- [9] Abou-Farha et al., Effect of dose reduction of dutasteride in combination with alpha-blockers in patients with LUTS/benign prostatic enlargement, Urology Annals, 2024
- [10] DHT rebound minimal after missed 5-ARI doses, Urology Times, 2004 (report of an AUA meeting presentation)
Alpha Health Finder Editorial Team
Editorial Team
The Alpha Health Finder editorial team researches and writes evidence-based men's health content. Articles are grounded in cited primary sources and reviewed against a fixed editorial standard before publication. We are a research and directory team — not your prescribing clinicians.
Looking for an online provider?
Find a qualified online provider — compare options vetted and reviewed by Alpha Health Finder.
One email a week. The research, not the hype.
What we published this week, what we changed our minds about, and what it means if you are on a protocol.
No spam, no selling your address. Unsubscribe in one click.




